Bavarian Nordic A/S (OTCMKTS:BVNRY) Short Interest Update

Bavarian Nordic A/S (OTCMKTS:BVNRY) was the recipient of a significant growth in short interest in the month of February. As of February 28th, there was short interest totalling 7,400 shares, a growth of 39.6% from the February 13th total of 5,300 shares. Based on an average daily volume of 15,500 shares, the short-interest ratio is presently 0.5 days. Currently, 0.0% of the company’s stock are sold short.

Bavarian Nordic A/S Trading Up 2.8 %

Shares of OTCMKTS BVNRY opened at $8.10 on Monday. The firm’s 50-day moving average price is $8.42 and its 200-day moving average price is $9.65. Bavarian Nordic A/S has a 1-year low of $6.86 and a 1-year high of $14.60. The firm has a market capitalization of $1.92 billion, a P/E ratio of 11.74 and a beta of 1.83.

Bavarian Nordic A/S (OTCMKTS:BVNRY) last posted its earnings results on Wednesday, March 5th. The company reported $0.47 EPS for the quarter, topping the consensus estimate of $0.40 by $0.07. The company had revenue of $299.48 million during the quarter, compared to the consensus estimate of $264.06 million. Bavarian Nordic A/S had a net margin of 18.33% and a return on equity of 10.65%. Equities research analysts forecast that Bavarian Nordic A/S will post 0.67 EPS for the current year.

About Bavarian Nordic A/S

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name.